Protein CD133 as a tumor stem cell marker

Grabovenko F.I.; Kisil O.V.; Pavlova G.V.; Zvereva M.E.

doi:https://doi.org/10.17116/neiro202286061113

Close metadata

Recommended articles:

Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118

TERTp mutation screening using digital droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95

Surgery for gliomas of Broca’s area. Burdenko's Journal of Neurosurgery. 2025;(6):38-45

Topic modeling of literature in glioma radiomics. Burdenko's Journal of Neurosurgery. 2025;(6-2):57-66

Reduction of cytoskeleton gene expression in tumor cells during lentivirus transduction. Molecular Genetics, Microbiology and Virology. 2025;(1):30-37

Comparative analysis of morphometric and histological characteristics of HPV-associated and HPV-independent vulvar squamous cell carcinoma. Russian Journal of Archive of Pathology. 2025;(3):26-32

Machine learning models for brain tumors differential diagnosis. Russian Journal of Preventive Medicine. 2025;(9):87-93

Heterogeneity of ALDH1, CD133 and CD34 expression in cancer stem cells of lung adenocarcinoma. Russian Journal of Archive of Pathology. 2025;(5):36-45

Abstract:

The CD133 protein is a large transmembrane glycoprotein. Despite multiple studies, the role of CD133 protein in cells is still poorly understood. Nevertheless, there is an association of CD133 protein with neoplastic transformation. This review summarizes data on CD133 protein, its structure, regulation of expression, molecular interactions and representation in cells that have undergone malignant transformation. Available data suggest that CD133 may have a great potential for predicting survival in various solid tumors. This protein can also be a marker of glioma.

Keywords:

CD133

prominin-1

glioma

tumor stem cells

marker of malignant transformation

carcinogenesis

diagnosis of cancer

Authors:

Grabovenko F.I.

Lomonosov Moscow State University

ORCID: 0000-0001-7308-395X

Kisil O.V.

Gause Institute of New Antibiotics

SPIN RSCI: 1153-8414
Scopus AuthorID: 36770374700
ORCID: 0000-0003-4799-1318

Pavlova G.V.

Sechenov First Moscow State Medical University;
Institute of Higher Nervous Activity and Neurophysiology;
Burdenko Neurosurgical Center

SPIN RSCI: 4633-8339
Scopus AuthorID: 7005650683
ORCID: 0000-0002-6885-6601

Zvereva M.E.

Lomonosov Moscow State University

SPIN RSCI: 2921-7129
Scopus AuthorID: 6602133750
ORCID: 0000-0002-7432-1574

Received:

19.08.2022

Accepted:

11.10.2022

Close metadata

References:

Rahman M, Deleyrolle L, Vedam-Mai V, Azari H, Abd-El-Barr M, Reynolds BA. The Cancer Stem Cell Hypothesis: Failures and Pitfalls. Neurosurgery. 2011;68(2):531-545. https://doi.org/10.1227/NEU.0b013e3181ff9eb5
Prager BC, Bhargava S, Mahadev V, Hubert CG, Rich JN. Glioblastoma Stem Cells: Driving Resilience through Chaos. Trends in Cancer. 2020;6(3):223-235. https://doi.org/10.1016/j.trecan.2020.01.009
Olatz C, Patricia GG, Jon L, Iker B, Carmen de la H, Fernando U, Gaskon I, Ramon PJ. Is There Such a Thing as a Genuine Cancer Stem Cell Marker? Perspectives from the Gut, the Brain and the Dental Pulp. Biology. 2020;9(12):426. https://doi.org/10.3390/biology9120426
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;3(7):730-737. https://doi.org/10.1038/nm0797-730
Bradshaw A, Wickremsekera A, Tan ST, Peng L, Davis PF, Itinteang T. Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Frontiers in Surgery. 2016;3:21. https://doi.org/10.3389/fsurg.2016.00021
Ludwig K, Kornblum HI. Molecular markers in glioma. Journal of Neuro-Oncology. 2017;134(3):505-512. https://doi.org/10.1007/s11060-017-2379-y
Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 2018;7(1). https://doi.org/10.1186/s40169-018-0198-1
Han M, Guo L, Zhang Y, Huang B, Chen A, Chen W, Liu X, Sun S, Wang K, Liu A, Li X. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis. Molecular Neurobiology. 2016;53(1):720-727. https://doi.org/10.1007/s12035-014-9018-9
Belyakova LI, Shevchenko AN, Sagakyants AB, Bondarenko ES, Shulgina OG, Ulyanova, EP, Filatova EV, Khomutenko IA. The number of cancer stem cells in the tumor tissue and perifocal tissue of non-muscle invasive bladder cancer. South Russian Journal of Cancer. 2022;3(1):6-14. (In Russ.). https://doi.org/10.37748/2686-9039-2022-3-1-1
Farid RM, Sammour SAE, Shehab ElDin ZA, Salman MI, Omran TI. Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma. Cancer Management and Research. 2019;11:4677-4690. https://doi.org/10.2147/CMAR.S198348
Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, Butler JM, Rabbany SY, Hormigo A. Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma. PLoS ONE. 2013;8(4):e62150. https://doi.org/10.1371/journal.pone.0062150
Fargeas CA, Lorico A, Corbeil D. Commentary: Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy? Frontiers in Oncology. 2021;11:712358. https://doi.org/10.3389/fonc.2021.712358
Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PØ. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer. 2008;122(4):761-768. https://doi.org/10.1002/ijc.23130
Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Laboratory Investigation. 2008;88(8):808-815. https://doi.org/10.1038/labinvest.2008.57
Calloni R, Cordero EAA, Henriques JAP, Bonatto D. Reviewing and Updating the Major Molecular Markers for Stem Cells. Stem Cells and Development. 2013;22(9):1455-1476. https://doi.org/10.1089/scd.2012.0637
Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nistér M, Ligon KL. Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. PLoS ONE. 2014;9(9):e106694. https://doi.org/10.1371/journal.pone.0106694
Rehfeld M, Matschke J, Hagel C, Willenborg K, Glatzel M, Bernreuther C. Differential expression of stem cell markers in proliferating cells in glioma. Journal of Cancer Research Clinical Oncology. 2021;147(10):2969-2982. https://doi.org/10.1007/s00432-021-03704-5
Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? American Journal of Translation Research. 2013;5(6):563-581.
Tan Y, Chen B, Xu W, Zhao W, Wu J. Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Molecular and Clinical Oncology. 2014;2(1):111-115. https://doi.org/10.3892/mco.2013.195
Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clinical Cancer Research. 2008;14(1):123-129. https://doi.org/10.1158/1078-0432.CCR-07-0932
Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro-Oncology. 2013;15(9):1151-1159. https://doi.org/10.1093/neuonc/not066
Wu B, Sun C, Feng F, Ge M, Xia L. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. Journal of Experimental and Clinical Cancer Research. 2015;34(1):44. https://doi.org/10.1186/s13046-015-0163-4
Vora P, Venugopal C, Salim SK, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, Williams R, Qazi MA, Chokshi C, Ding A, Subapanditha M, Savage N, Mahendram S, Ford E, Adile AA, McKenna D, McFarlane N, Huynh V, Wylie RG, Pan J, Bramson J, Hope K, Moffat J, Singh S. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020;26(6):832-844.e6. https://doi.org/10.1016/j.stem.2020.04.008
Li B, McCrudden CM, Yuen HF, Xi X, Lyu P, Chan KW, Zhang SD, Kwok HF. CD133 in brain tumor: the prognostic factor. Oncotarget. 2016;8(7):11144-11159. https://doi.org/10.18632/oncotarget.14406
Pallini R, Ricci-Vitiani L, Banna Gl, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca Lm, De Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clinical cancer research. 2008;14(24):8205-8212. https://doi.org/10.1158/1078-0432.CCR-08-0644
Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117(1):162-174. https://doi.org/10.1002/cncr.25581
Christensen K, Schrøder HD, Kristensen BW. CD133 identifies perivascular niches in grade II—IV astrocytomas. Journal of Neuro-Oncology. 2008;90(2):157-170. https://doi.org/10.1007/s11060-008-9648-8
Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Journal of Translational Medicine. 2012;10(1):250. https://doi.org/10.1186/1479-5876-10-250
Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology. 2011;31(5):494-502. https://doi.org/10.1111/j.1440-1789.2010.01194.x
Dahlrot RH. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Danish Medical Journal. 2014;61(10):B4944.
Wu X, Wu F, Xu D, Zhang T. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. Journal of Neuro-Oncology. 2016;127(2):221-232. https://doi.org/10.1007/s11060-015-2039-z
He J, Shan Z, Li L, Liu F, Liu Z, Song M, Zhu H. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncology Reports. 2011;26(5):1305-1313. https://doi.org/10.3892/or.2011.1393
Pavlova G, Kolesnikova V, Samoylenkova N, Drozd S, Revishchin A, Shamadykova D, Usachev DY, Kopylov A. A Combined Effect of G-Quadruplex and Neuro-Inducers as an Alternative Approach to Human Glioblastoma Therapy. Frontiers in Oncology. 2022;12:880740. https://doi.org/10.3389/fonc.2022.880740
Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749-1758. https://doi.org/10.1038/sj.onc.1210811
Weng CC, Kuo KK, Su HT, Hsiao PJ, Chen YW, Wu DC, Hung WC, Cheng KH. Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation. Pancreas. 2016;45(3):443-457. https://doi.org/10.1097/MPA.0000000000000460
Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene. 2013;32(26):3119-3129. https://doi.org/10.1038/onc.2012.331
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009;28(45):3949-3959. https://doi.org/10.1038/onc.2009.252
Tian W, Zhu W, Jiang J. miR-150-5p suppresses the stem cell-like characteristics of glioma cells by targeting the Wnt/β-catenin signaling pathway. Cell Biology International. 2020;44(5):1156-1167. https://doi.org/10.1002/cbin.11314
Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Research. 2009;19(6):683-697. https://doi.org/10.1038/cr.2009.43
Manoranjan B, Chokshi C, Venugopal C, Subapanditha M, Savage N, Tatari N, Provias J P, Murty NK, Moffat J, Doble BW, Singh SK. A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 2020;39(7):1590-1599. https://doi.org/10.1038/s41388-019-1086-x
Mak AB, Nixon AML, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, Moffat J. Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation. Cell Reports. 2012;2(4):951-963. https://doi.org/10.1016/j.celrep.2012.09.016
Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R. Wnt/β-Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells. Science. 2012;336(6088):1549-1554. https://doi.org/10.1126/science.1218370
Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, McLaughlin M, Veenstra TD, Nusse R, McCrea PD, Artandi SE. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460(7251):66-72. https://doi.org/10.1038/nature08137
Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MCM, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME. Stem cell-related «self-renewal» signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of Clinical Oncology. 2008;26(18):3015-3024. https://doi.org/10.1200/JCO.2007.15.7164
Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010;12(1):49-57. https://doi.org/10.1093/neuonc/nop007
Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. International Journal of Radiation Oncology, Biology, Physics. 2007;67(1):1-5. https://doi.org/10.1016/j.ijrobp.2006.09.037
Alibolandi M, Abnous K, Anvari S, Mohammadi M, Ramezani M, Taghdisi SM. CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer. Artificial Cells, Nanomedicine, and Biotechnology. 2018;46(suppl 1):1159-1169. https://doi.org/10.1080/21691401.2018.1446969
Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Letters. 2013;330(1):84-95. https://doi.org/10.1016/j.canlet.2012.11.032
Abdoli Shadbad M, Hosseinkhani N, Asadzadeh Z, Brunetti O, Silvestris N, Baradaran B. The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis. Frontiers in Oncology. 2021;11:722833. https://doi.org/10.3389/fonc.2021.722833